FDA Approved OGSIVEO as the FIRST and ONLY treatment for Desmoid Tumours
The U.S Food and Drug Administration (FDA) approved OGSIVEO (nirogacestat) for the treatment of progressive desmoid tumors in adults who require systemic treatment. OGSIVEO is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. OGSIVEO is a first-in-class medication developed by SPRINGWORKS THERAPEUTICS INC. OGSIVEO granted a Priority Review, FDA Fast Track and Breakthrough Therapy designations for the subject indication by...

US FDA DATABASES – A PRIME TOOL FOR REGULATORY INTELLIGENCE
The Food and Drug Administration (FDA) is the federal system that approves any drug related to humans. The Agency provides the sufficient information that enables the sponsors and industry to gather the data and requirements from time-to time. These data can be used as a regulatory intelligence tool to understand the agency’s current thinking and meet the applicable requirements and keep focus on the competitor analysis. There are several databases in the FDA to track the necessary information...

Impurities – Classification, Thresholds Limits, Specification with RTR Considerations in APIs and Finished Products
Every product should have a sufficient level of quality to ensure its efficacy and safety. The impurities/degradation products are the ones that arise during different stages of synthesis, manufacture and storage. They should be controlled at certain level to maintain the required quality of the drug substance/product. The potential impurities are most likely to arise during the synthesis of drug substance, purification, manufacturing and storage of the drug substance/drug product. The...

Stability data Requirements for a Marketing Authorization Application
Any drug substance or drug product has to maintain the same quality, safety and efficacy throughout the lifecycle of a product. Generally, the quality of a drug substance or drug product varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light. As we understood the quality of substance or product is varying in the presence of temperature and humidity over the period of time, any sponsor/applicant needs to provide supporting data and...
FDA Novel Drug Approvals in January 2022
QUVIVIQ ITEMDESCRIPTIONSPONSOR/HOLDERIDORSIA PHARMACEUTICALS LTDApplication No.#214985Application TypeNDAActive IngredientDaridorexantDosage FormTABLETRoute of AdministrationORALStrengthsEQ 25mg BaseIndication for UseTreatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenanceApproval Date07/01/2022 CIBINQO ITEMDESCRIPTIONSPONSOR/HOLDERPFIZER INCApplication No.#213871Application TypeNDAActive IngredientAbrocitinibDosage FormTABLETRoute of...